Monitoring hepatitis C treatment uptake in Australia: Issue #13, July 2023
Notice bibliographique
Résumé
A total of 105,024 individuals have initiated direct acting antiviral (DAA) treatment for chronic hepatitis C virus (HCV) infection in Australia, including 100,684 individuals through Pharmaceutical Benefits Scheme (PBS) during 2016 to 2022, and an estimated 4,340 individuals through early DAA access avenues in 2014-15. In 2022, 5,205 individuals initiated treatment (first course), increasing from 1,141 in the first quarter to 1,432 in the last quarter of 2022. The recent increase in treatment uptake could be explained by enhanced HCV testing programs implemented in the community and prisons in several jurisdictions. Among individuals initiating DAA treatment during 2016 to 2022 (n=100,684), 68% were men, and median age was 47 years (quartiles 1-3: 38-57). Since August 2018 when both pan-genotypic regimens were available (i.e., sofosbuvir/velpatasvir and glecaprevir/pibrentasvir), 53% of individuals have been initiated on sofosbuvir/velpatasvir, 41% on glecaprevir/pibrentasvir, and 6% on other regimens. Most individuals initiating DAA treatment received their prescriptions from general practitioners (GPs; 46%), followed by gastroenterologists (35%). Overall, 52% of individuals were initiated on treatment by specialists, and 48% by non-specialists (i.e., GPs and nurse practitioners). A total of 2,048 individuals were initiated on treatment by nurse practitioners, increasing from 92 in 2017 to 535 in 2022. Among individuals initiating DAA treatment during 2016 to 2022, 8.6% discontinued treatment, including 4.0% early discontinuation (i.e., dispensed 28 days of treatment) and 4.6% late discontinuation (i.e., dispensed at least 56 days of treatment, but not all recommended duration). The proportion of early discontinuation increased from >3% in 2016 to 8.5% in mid-2021 followed by a plateau phase and then slight decrease in 2022. Among individuals who discontinued treatment, 26% received re-treatment. Among individuals initiating DAA treatment during 2016 to 2022, 8.5% received at least one course of re-treatment. Among re-treatment initiations, an estimated 57% were for HCV re-infection and 43% for treatment failure. The number of re-treatment initiations for treatment failure increased during the second quarter of 2019, corresponding to sofosbuvir/velpatasvir/voxilaprevir availability through PBS (April 2019), and has decreased since. The number of re-treatment initiations for HCV re-infection increased until mid-2020, stabilised during 2020-21, and increased again in 2022. This latest increase could be the result of enhanced HCV testing programs implemented in several jurisdictions through which many individuals with HCV re-infection were diagnosed and linked to clinical care.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,002 | 0,003 |
| Méta-épidémiologie (sens large) | 0,003 | 0,002 |
| Bibliométrie | 0,003 | 0,004 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,001 |
| Science ouverte | 0,002 | 0,001 |
| Intégrité de la recherche | 0,003 | 0,003 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,003 | 0,021 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; les deux têtes enseignantes s’accordent sur ce qui est montré ici.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».